

Amoxicillin + clavulanic acid

Essential medicine status

General description

Amoxicillin is an extended spectrum penicillin antibiotic. Clavulanic acid is a beta-lactamase inhibitor.

INN

Amoxicillin + clavulanic acid

ATC codes

[J01CR02](#)

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

EML status history

First added in 1997 ([TRS 882](#)) for [Bacterial infection of unspecified site](#)

Added in 2017 ([TRS 1006](#)) for [Acute otitis media](#)

Added in 2017 ([TRS 1006](#)) for [Infectious cystitis](#)

Added in 2017 ([TRS 1006](#)) for [Chronic obstructive pulmonary disease with acute exacerbation](#)

Added in 2017 ([TRS 1006](#)) for [Acute sinusitis](#)

Added in 2017 ([TRS 1006](#)) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Added in 2017 ([TRS 1006](#)) for [Osteomyelitis or osteitis](#)

Added in 2017 ([TRS 1006](#)) for [Bacterial infection of joint](#)

Removed in 2017 ([TRS 1006](#)) for [Bacterial infection of unspecified site](#)

Added in 2017 ([TRS 1006](#)) for [Neutropenia](#)

Added in 2017 ([TRS 1006](#)) for [Peritoneal abscess](#)

Added in 2017 ([TRS 1006](#)) for [Peritonitis](#)

Added in 2017 ([TRS 1006](#)) for [Bacterial pneumonia](#)

Added in 2017 ([TRS 1006](#)) for [Other specified pneumonia](#)

Added in 2019 ([TRS 1021](#)) for [Other specified prophylactic measures](#)

Added in 2019 ([TRS 1021](#)) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Wikipedia

[Amoxicillin + clavulanic acid](#)

DrugBank

[Amoxicillin](#),

[Clavulanic acid \(Clavulanate\)](#)

Recommendations

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

[Chronic obstructive pulmonary disease with acute exacerbation](#) [Infectious cystitis](#) [Acute sinusitis](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Neutropenia \(low-risk\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritonitis \(mild-moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

Second choice

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Acute otitis media](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)